𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers

✍ Scribed by D. L. Wolf; J. J. Ferry; A. E. Hearron; M. O. Froeschke; J. R. Luderer


Publisher
Springer
Year
1993
Tongue
English
Weight
653 KB
Volume
44
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis


We have studied the effects of intravenous nicorandil, a mixed arterial and venous vasodilator, in 48 healthy volunteers. Nicorandil (20, 28, 39, 54, 74, 103, 144, or 200 micrograms.kg-1) or placebo were given over 5 min to subjects supine (16 subjects, 2 doses) or sitting (32 subjects, 1 dose) in a single-blind crossover design. Electrocardiographic intervals, blood pressure, and heart rate were measured before and for 8 h after dosing. Blood and urine safety laboratory studies were also performed before and after dosing. All intravenous infusions of nicorandil and placebo were well tolerated and there were no clinically important safety concerns. The most frequent adverse event after nicorandil was headache (24 events by 19 subjects), although its occurrence was not strictly dose related. One subject experienced transient symptomatic hypotension (144 micrograms.kg-1). Mean plasma nicorandil concentrations were dose-related and fell with a half-life of 0.7 to 1.2 h. Systemic clearance and volume of distribution tended to decrease as dose increased. Sitting subjects showed marginally lower (< 20%) systemic clearances and larger values of Cmax and AUC. Nicorandil produced dose-related reductions in blood pressure, with consistent statistically significant differences from placebo after the 144 and 200 micrograms.kg-1 doses. The falls in blood pressure were greater for diastolic pressure and in this supine position. At 200 micrograms.kg-1, the mean falls in systolic/diastolic pressures (mm Hg) during the first hour were 10.9/14.7 supine and 6.1/9.1 sitting; systolic pressure returned to baseline after 8 h and diastolic pressure after 4 h.(ABSTRACT TRUNCATED AT 250 WORDS)


πŸ“œ SIMILAR VOLUMES


The pharmacokinetics and haemodynamic ef
✍ D. L. Wolf; A. E. Hearron; C. M. Metzler; J. J. Ferry; M. O. Froeschke; J. R. Lu πŸ“‚ Article πŸ“… 1993 πŸ› Springer 🌐 English βš– 636 KB

We have studied the pharmacokinetics and haemodynamic effects of nicorandil after a 12-h infusion. Nicorandil is a mixed vasodilator combining the actions of a nitrate and a potassium channel opener. Nicorandil was infused for 12 h in 21 healthy volunteers at rates of 0.05, 0.10, and 0.20 microgram.

The pharmacokinetics of oral and intrave
✍ A. F. Clarke; D. B. Jack; M. J. Kendall; S. R. Smith πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 276 KB πŸ‘ 2 views

The pharmacokinetics of prenalterol in healthy young volunteers after i.v. and oral dosing has been studied. There is evidence of non-linearity following the i.v. dosing. Evidence of dose-dependent pharmacokinetics following i.v. dosing has been obtained. The sustained-release formulation is very ef

Pharmacokinetics of moxisylyte in health
✍ Pierre Costa; Francoise Bressolle; Brigitte Sarrazin; Jacqueline Mosser; Marc Ga πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 617 KB

The concentration-time profiles of metabolites of moxisylyte, an alpha-adrenergic receptor blocking agent, in the plasma of 12 healthy volunteers were investigated after intravenous (iv) and intracavernous (ic) administrations. The study was conducted in open, randomized, Latin Squares. Plasma level